NASHVILLE, TN (WSMV) – An allergy treatment is showing great promise, for patients who are severely ill from COVID-19.

Dexamethosone is a steroid that reduces inflammation in a wide range of medical conditions.

British researchers began tests on severely ill COVID-19 patients on ventilators. It showed an amazing ability to fight COVID-19.

"And it’s becoming part of routine medical care here," Vanderbilt Infectious Disease Expert Dr William Shaffner said.

Shaffner said Dexamethasone is so effective, it's become part of an arsenal of life saving drugs to get severely ill COVID-19 patients back on their feet

Along with Dexamethasone, Resdeivir and Plazma, all of these things have improved our capacity to get people off ventilators, and wonderfully back home," Shaffner said.

The drug is relatively cheap. But, given its ability to fight a virus that has killed almost 125,000 people in the U.S. will it stay cheap

"This is a drug that can be manufactured in a very straight forward way, manufacturers will be able to keep up with demand," Shaffner said. "I hope, that would not happen, although that's always a concern."

Doctors are continually learning about COVID-19 and how to treat it. is now with you on the go! Get the latest news updates and video, 4WARN weather forecast, weather radar, special investigative reports, sports headlines and much more from News4 Nashville.

>> Click/tap here to download our free mobile app. <<

Copyright 2020 WSMV (Meredith Corporation). All rights reserved.


Alan Frio is the anchor of News4's evening newscasts on Saturdays and Sundays.

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.